Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pliant Therapeutics, Inc.

1.62
-0.0700-4.14%
Post-market: 1.630.0100+0.62%17:49 EDT
Volume:2.83M
Turnover:4.69M
Market Cap:99.20M
PE:-0.47
High:1.70
Open:1.66
Low:1.60
Close:1.69
Loading ...

BUZZ-Pliant Therapeutics slumps as it halts enrollment in lung disease mid-stage trial

Reuters
·
10 Feb

Pliant Therapeutics Is Maintained at Buy by Needham

Dow Jones
·
10 Feb

Piper Sandler Remains a Buy on Pliant Therapeutics (PLRX)

TIPRANKS
·
10 Feb

Pliant Therapeutics Cut to Neutral From Buy by HC Wainwright & Co.

Dow Jones
·
10 Feb

Pliant Therapeutics Inc : H.c. Wainwright Cuts to Neutral Rating

THOMSON REUTERS
·
10 Feb

Pliant Therapeutics Shares Fall on Drug Trial Pause After Safety Board Review

Dow Jones
·
10 Feb

RBC Downgrades Pliant Therapeutics to Sector Perform From Outperform, Cuts Price Target to $4 From $45, Keeps Speculative Risk

MT Newswires Live
·
10 Feb

Pliant Therapeutics Inc : RBC Cuts to Sector Perform From Outperform

THOMSON REUTERS
·
10 Feb

Pliant Therapeutics Suspends Enrollment in Phase 2b Idiopathic Pulmonary Fibrosis Trial

MT Newswires Live
·
10 Feb

Pliant Therapeutics Falls 55.8% Premarket After Co Pauses Enrollment for Lung Disease Treatment Trial

THOMSON REUTERS
·
10 Feb

BUZZ-Pliant pauses enrollment for lung disease treatment trial

Reuters
·
08 Feb

Pliant Therapeutics Shares Down 67% at $2.59 in After the Bell Trading Following Update on Trial for Patients With Idiopathic Pulmonary Fibrosis

THOMSON REUTERS
·
08 Feb

Pliant Therapeutics trading resumes

TIPRANKS
·
08 Feb

Pliant Therapeutics pauses enrollment, dosing in BEACON-IPF Phase 2b trial

TIPRANKS
·
08 Feb

BRIEF-Pliant Therapeutics Provides Update On BEACON-IPF, A Phase 2B/3 Trial In Patients With Idiopathic Pulmonary Fibrosis

Reuters
·
08 Feb

Pliant Therapeutics Inc - Informing Global Regulatory Authorities

THOMSON REUTERS
·
08 Feb